PMID- 37029069
OWN - NLM
STAT- MEDLINE
DCOM- 20230807
LR  - 20230807
IS  - 1444-2892 (Electronic)
IS  - 1443-9506 (Linking)
VI  - 32
IP  - 7
DP  - 2023 Jul
TI  - Cardiac Regeneration Using Pluripotent Stem Cells and Controlling Immune 
      Responses.
PG  - 836-843
LID - S1443-9506(23)00108-7 [pii]
LID - 10.1016/j.hlc.2022.12.014 [doi]
AB  - Pluripotent stem cell (PSC)-derived cardiomyocytes are a promising source of 
      cells in myocardial regeneration therapy for end-stage heart failure. Because 
      most previous reports have focussed on xenotransplantation models using 
      immunocompromised animals, studies on immune rejection in allogeneic 
      transplantation models are needed for preclinical and clinical applications. 
      Human leukocyte antigen (HLA) plays an important role in allogeneic 
      transplantation, and cell bank projects are currently underway worldwide to stock 
      induced pluripotent stem cells (iPSCs) generated from healthy individuals with 
      homozygous HLA haplotypes. However, it is difficult to stock iPSCs that match the 
      entire population in these cell banks; thus, several groups have produced 
      hypoimmunogenic PSCs by knocking out HLA. These HLA-knockout PSCs were able to 
      avoid rejection by T cells but still suffered rejection by natural killer (NK) 
      cells caused by 'missing self-recognition'. Recent studies have attempted to 
      generate hypoimmunogenic PSCs with gene editing to inhibit NK cell activation. 
      Regenerative medicine using autologous iPSCs can be an ideal transplantation 
      therapy, but, currently, there are major hurdles to its practical application. 
      Hopefully, further research will resolve these issues. This review provides an 
      overview of the current understanding and progress in this field.
CI  - Copyright (c) 2023 Australian and New Zealand Society of Cardiac and Thoracic 
      Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). 
      Published by Elsevier B.V. All rights reserved.
FAU - Ichimura, Hajime
AU  - Ichimura H
AD  - Department of Regenerative Science and Medicine, Shinshu University School of 
      Medicine, Matsumoto, Japan; Department of Surgery, Division of Cardiovascular 
      Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
FAU - Chino, Shuji
AU  - Chino S
AD  - Department of Surgery, Division of Cardiovascular Surgery, Shinshu University 
      School of Medicine, Matsumoto, Japan.
FAU - Shiba, Yuji
AU  - Shiba Y
AD  - Department of Regenerative Science and Medicine, Shinshu University School of 
      Medicine, Matsumoto, Japan; Institute for Biomedical Sciences, Shinshu 
      University, Matsumoto, Japan. Electronic address: yshiba@shinshu-u.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230405
PL  - Australia
TA  - Heart Lung Circ
JT  - Heart, lung & circulation
JID - 100963739
SB  - IM
MH  - Animals
MH  - Humans
MH  - *Pluripotent Stem Cells
MH  - *Induced Pluripotent Stem Cells
MH  - Myocytes, Cardiac
MH  - Immunity
MH  - Regeneration
OTO - NOTNLM
OT  - Allogeneic transplantation
OT  - Cardiomyocytes
OT  - Pluripotent stem cells
EDAT- 2023/04/08 06:00
MHDA- 2023/08/07 06:42
CRDT- 2023/04/07 22:05
PHST- 2022/07/22 00:00 [received]
PHST- 2022/11/02 00:00 [revised]
PHST- 2022/12/05 00:00 [accepted]
PHST- 2023/08/07 06:42 [medline]
PHST- 2023/04/08 06:00 [pubmed]
PHST- 2023/04/07 22:05 [entrez]
AID - S1443-9506(23)00108-7 [pii]
AID - 10.1016/j.hlc.2022.12.014 [doi]
PST - ppublish
SO  - Heart Lung Circ. 2023 Jul;32(7):836-843. doi: 10.1016/j.hlc.2022.12.014. Epub 
      2023 Apr 5.